Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.82), $0.03 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $48.5 million versus the consensus estimate of $51.92 million.

Cash, cash equivalents and marketable securities, as of March 31, 2022, totaled $603.4 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.